Amphotericin B lipid complex in the treatment of invasive fungal infections: Results of the collaborative exchange of antifiuigal research (CLEAR), an industry-supported patient registry

Clinical Infectious Diseases

Volumn 40, Issue SUPPL. 6, 2005, Pages

  Pappas, Peter G ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ADOLESCENT; ADULT; AGED; CHILD; CONFERENCE PAPER; DATA ANALYSIS; DATA BASE; DEMOGRAPHY; DRUG SAFETY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; PUBLICATION; REGISTER; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; MYCOSES; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; REGISTRIES;

EID: 17644406698     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/429329     Document Type: Conference Paper

References (8)

1. Rex JH, Walsh TJ, Nettleman M, et al. Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis 2001; 33:95-106.
2. Janoff AS, Boni LT, Popescu MC, et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl. Acad Sci USA 1988; 85:6122-6.
3. Perfect JR, Wright KA. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidiasis. J Antimicrob Chemother 1994; 33:73-81.
4. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new "gold standard." Clin Infect Dis 2003; 37:415-25.
5. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32:686-93.
6. Wingard JR. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant 1997; 19:343-7.
7. Harbarth S, Burke JP, Lloyd JF, Evans RS, Pestotnik SL, Samore MH. Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 2002; 35:e120-7.
8. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.